ArticleFrontiers in oncology2025
Dedifferentiated adamantinoma of long bones: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging Analysis for Metastatic Risk Assessment in Adamantinoma: The Aid of Radiology in the Absence of a Histological Grading-An MRI-Based Risk Model Proposal.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a rare case of dedifferentiated adamantinoma. The 48-year-old male patient was initially diagnosed with classic adamantinoma in the right fibula and underwent curettage. Two years postoperatively, the patient presented with progressive swelling and pain in the same region. Imaging disclosed an expansile lesion with mixed lytic and sclerotic changes involving the medulla and adjacent soft tissue. A biopsy was performed, and a diagnosis of classic adamantinoma was made. Considering the significant clinical symptoms and imaging features, a below-knee amputation was performed. Histologically, the tumor exhibited two distinct patterns: classic adamantinoma juxtaposed to a dedifferentiated component, characterized by chondrosarcomatous areas with moderate cellularity and abundant hyaline cartilage matrix. Myxoid areas containing malignant cartilage cells of myxoid chondrosarcoma were also observed. Immunohistochemically, the dedifferentiated areas showed complete loss of epithelial markers. At a two-year follow-up, the patient remains free of recurrence or metastasis. Dedifferentiated adamantinoma is an exceedingly rare primary bone tumor malignancy lacking specific clinical manifestations. In our case, the initial biopsy specimen revealed only epithelial cells, leading to an underdiagnosis of classic adamantinoma until further sampling revealed the dedifferentiated component. It underscores the importance of thorough sampling, close radiologic-pathologic correlation, and a multidisciplinary framework for accurate diagnosis and optimal management of complex bone tumors. Early recognition of the dedifferentiated features can guide appropriate surgical management and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.